Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer: A Phase 3 Randomized Clinical Trial

In this study (n=647), 5-year disease-free survival was higher with paclitaxel and carboplatin vs. standard treatment (3 cycles cyclophosphamide, epirubicin and 5-FU then 3 cycles of docetaxel; 86.5% vs 80.3%; HR 0.65; 95% CI 0.44-0.96; P =0.03), with similar overall survival.


JAMA Oncology